MX2022003301A - Derivado de interleucina-2. - Google Patents

Derivado de interleucina-2.

Info

Publication number
MX2022003301A
MX2022003301A MX2022003301A MX2022003301A MX2022003301A MX 2022003301 A MX2022003301 A MX 2022003301A MX 2022003301 A MX2022003301 A MX 2022003301A MX 2022003301 A MX2022003301 A MX 2022003301A MX 2022003301 A MX2022003301 A MX 2022003301A
Authority
MX
Mexico
Prior art keywords
derivative
cysteine residue
closed
closed module
wild
Prior art date
Application number
MX2022003301A
Other languages
English (en)
Inventor
Qian Zheng
Wei Zhang
Yao Zhao
Lujia Peng
Jianyun Guo
Xiaoting Zhu
Jianjun Zhang
Tingting Wei
Huijie Liu
Jishu Wang
Original Assignee
Leto Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leto Laboratories Co Ltd filed Critical Leto Laboratories Co Ltd
Publication of MX2022003301A publication Critical patent/MX2022003301A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describe un derivado de IL-2. Al introducir por lo menos un residuo de cisteína en base a IL-2 de tipo silvestre, el plano de enlace del derivado de IL-2 y la subunidad del receptor a se bloquea parcialmente o completamente, mientras que la afinidad del derivado de IL-2 al complejo de subunidades del receptor ß y ? se retiene básicamente. También se describe un complejo, que comprende: un derivado de IL-2, que se introduce con un tercer residuo de cisteína en base a IL-2 de tipo silvestre; y un módulo de bloqueo, que tiene o se introduce con un cuarto residuo de cisteína; en donde el tercer residuo de cisteína en el derivado de IL-2 y el cuarto residuo de cisteína en el módulo de bloqueo son capaces de formar un enlace de disulfuro intermolecular, para de esta manera formar un complejo del derivado de IL-2 y el módulo de bloqueo; y en donde el plano de enlace del derivado de IL-2 y la subunidad del receptor a se bloquea parcialmente o completamente, mientras que la afinidad del derivado de IL-2 al complejo de subunidades del receptor ß y ? se retiene básicamente.
MX2022003301A 2019-12-17 2020-01-07 Derivado de interleucina-2. MX2022003301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911302355.5A CN111018961B (zh) 2019-12-17 2019-12-17 白介素-2衍生物
PCT/CN2020/070748 WO2021120350A1 (zh) 2019-12-17 2020-01-07 白介素-2衍生物

Publications (1)

Publication Number Publication Date
MX2022003301A true MX2022003301A (es) 2022-04-12

Family

ID=70210189

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003301A MX2022003301A (es) 2019-12-17 2020-01-07 Derivado de interleucina-2.

Country Status (11)

Country Link
US (1) US20220363731A1 (es)
EP (1) EP4023666A4 (es)
JP (1) JP2023514003A (es)
KR (1) KR20220113918A (es)
CN (4) CN114478743A (es)
AU (1) AU2020406768A1 (es)
BR (1) BR112022003712A2 (es)
CA (1) CA3151681A1 (es)
GB (1) GB2604238A (es)
MX (1) MX2022003301A (es)
WO (1) WO2021120350A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4130027A1 (en) 2020-03-31 2023-02-08 Hanmi Pharm. Co., Ltd. Novel immunoactive interleukin 2 analog
CA3168737A1 (en) * 2020-04-21 2021-10-28 Jiaxi WU Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
CN114369153A (zh) * 2020-10-18 2022-04-19 北京志道生物科技有限公司 一种白介素-2突变体
CN114380919A (zh) 2020-10-18 2022-04-22 北京志道生物科技有限公司 经修饰的il-2分子及其用途
CN118019849A (zh) * 2021-09-26 2024-05-10 上海药明生物技术有限公司 Il-2变体及其融合蛋白
CN114306576A (zh) * 2022-01-11 2022-04-12 北京志道生物科技有限公司 一种防止il-2衍生物蛋白复合体聚集及非共价连接蛋白亚基脱落的制剂
CN114349843B (zh) * 2022-01-18 2024-05-14 浙江博锐生物制药有限公司 白细胞介素-2衍生物及其制备方法和应用
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
WO2024104444A1 (zh) * 2022-11-17 2024-05-23 南通壹宸生物医药科技有限公司 Il-2突变体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208345C (zh) * 2002-07-23 2005-06-29 重庆大学 重组人白细胞介素－2的三突变体及制备方法
CA2656700A1 (en) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
HUE051414T2 (hu) * 2014-08-11 2021-03-01 Delinia Inc Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére
MX2020001336A (es) * 2017-08-03 2020-08-20 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades autoinmunes.
KR20200086312A (ko) * 2017-11-08 2020-07-16 야페이 상하이 바이오로그 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 생체분자의 컨쥬게이트 및 이의 용도
KR20200103681A (ko) * 2017-12-27 2020-09-02 쿄와 기린 가부시키가이샤 Il-2 개변체
IL277572B2 (en) * 2018-03-28 2024-05-01 Ascendis Pharma Oncology Div A/S IL-2 conjugates
AU2020285636A1 (en) * 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof

Also Published As

Publication number Publication date
CA3151681A1 (en) 2021-06-24
CN111018961A (zh) 2020-04-17
JP2023514003A (ja) 2023-04-05
KR20220113918A (ko) 2022-08-17
CN111018961B (zh) 2022-03-18
GB202201999D0 (en) 2022-03-30
AU2020406768A1 (en) 2022-03-03
EP4023666A4 (en) 2023-03-22
BR112022003712A2 (pt) 2022-10-11
US20220363731A1 (en) 2022-11-17
CN114478743A (zh) 2022-05-13
CN114524873A (zh) 2022-05-24
GB2604238A (en) 2022-08-31
EP4023666A1 (en) 2022-07-06
WO2021120350A1 (zh) 2021-06-24
CN114437198A (zh) 2022-05-06

Similar Documents

Publication Publication Date Title
MX2022003301A (es) Derivado de interleucina-2.
PH12016502358A1 (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
MX2021009352A (es) Compuestos de fijacion al receptor de il -2.
MX2020014027A (es) Dise?o de novo de mimeticos de interleucina potentes y selectivos.
TR201809594T4 (tr) Fikstür.
NZ722668A (en) Anti-her3 antibody-drug conjugate
MY178760A (en) Monocyclic pyridine derivative
MX2019005310A (es) Accesorio de iluminacion para cascos de soldadura.
TWD202667S (zh) 閘道器
MX2020010657A (es) Derivados de oxadiazolina.
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
WO2018195521A3 (en) Magnetic quick-release mechanism
ZA202106602B (en) Claudin 6 antibodies and uses thereof
MX2021005593A (es) Miméticos de interleucina dividida y sus usos.
MX2021014038A (es) Interfaz de conexion mecanica.
WO2020131586A3 (en) Methods for identifying neoantigens
WO2018174668A3 (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
EP3911315A4 (en) SOLID MICRONIZED MELATONIN COMPOSITION
EP3901147A4 (en) ACYLAMINO BRIDGE HETEROCYCLIC COMPOUND, ASSOCIATED COMPOSITION AND USE
MY198519A (en) Composition for browning inhibition and use of same
MX2021015473A (es) Nuevo anticuerpo específico para cthrc1 y su uso.
EP3739022A4 (en) MEMBRANE FILTERABLE, PHYSICALLY PRE-TREATED BIOMASS COMPOSITION
EP3793360A4 (en) METHODS AND COMPOSITIONS FOR SUBSTITUTED 2,5-DICETOPIPERAZINE ANALOGS
BR102018075691A8 (pt) Articulação da aba do airbag
MX2020012745A (es) Compuestos de uracilo y composición para controlar artrópodos dañinos que los contiene.